Quantum BioPharma Featured in CTV W5 Investigation on Alleged Market Manipulation
TL;DR
Quantum BioPharma's $700 million lawsuit against CIBC and RBC could expose market manipulation, potentially creating a legal advantage for investors monitoring stock spoofing allegations.
Quantum BioPharma alleges stock spoofing through millions of illegal orders from bank platforms, detailed in CTV News' W5 series and supported by Canadian exchange data.
Quantum BioPharma's lawsuit aims to protect market integrity, supporting their development of Lucid-MS to potentially treat multiple sclerosis and improve patient outcomes.
CTV News' W5 aired Part 2 investigating Quantum BioPharma's claims of widespread market manipulation tied to their $700 million lawsuit against major Canadian banks.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has been featured in Part 2 of CTV News' investigative program W5's three-part series examining the company's allegations of stock spoofing tied to its USD $700 million lawsuit against CIBC and RBC. The segment, reported by award-winning journalist Jon Woodward, highlights the company's claims of widespread market manipulation and its impact on Quantum BioPharma's efforts to advance Lucid-MS, a potential multiple-sclerosis treatment. CEO Zeeshan Saeed and Co-Executive Chair Anthony Durkacz reiterated their concerns about the alleged activity, noting that Canadian exchange data cited in the lawsuit points to millions of purportedly illegal orders originating from bank platforms.
The company maintains that these alleged market manipulation activities have significantly impacted its ability to advance its lead compound, Lucid-MS, which is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma is focused on the research and development of this potential treatment for neurodegenerative disorders. The company's broader portfolio includes innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development.
Quantum BioPharma also retains ownership of 20.11% of Unbuzzd Wellness Inc. as of March 31, 2025, with an agreement that includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum BioPharma total $250 million, after which the royalty drops to 3% in perpetuity. The company retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Additional information about the company is available through its newsroom at https://ibn.fm/QNTM.
The investigative coverage comes as part of broader market scrutiny, with the press release disseminated through InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio that provides wire-grade press release syndication and corporate communications solutions. The platform's full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer. The W5 investigation's focus on alleged market manipulation practices raises significant questions about their potential impact on biopharmaceutical companies working to develop treatments for serious medical conditions, particularly when such activities might affect funding and market perception during critical development phases.
Curated from InvestorBrandNetwork (IBN)
